ReviewArchives of microbiology2023
Factors involved in heterologous expression of proteins in E. coli host.
Review in Archives of microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Gentamicin and d-serine selective pressure to improve the homogeneity of cells expressing target proteins.Synthetic and systems biotechnology · 2027Article
- High-level fed-batch production of recombinant type II cholesterol oxidase fromBiotechnology reports (Amsterdam, Netherlands) · 2026Article
- Secreted chimeric proteins as a strategy to correct SOX17 deficiency and attenuate the malignant phenotype of cholangiocarcinoma cells: a proof-of-concept study.Acta pharmacologica Sinica · 2026Article
- Heterologous Systems in the Functional Characterization of Proteins from Phytopathogenic Fungi: A Systematic Review.Molecular biotechnology · 2026Article
- A recombinant xylose reductase enzyme with biotechnological potential for xylitol production.Archives of microbiology · 2026Article
- Recombinant Production and Immunological Evaluation of Tobamovirus fructirugosum (ToBRFV) Capsid and Movement Proteins.Molecular biotechnology · 2026Article
- Designing strategies for high-level production of peptide-N-glycosidase F (PNGase F) from Flavobacterium meningosepticum using high cell density fed-batch culture of E. coli.Bioprocess and biosystems engineering · 2026Article
- Integrating Vibrio natriegens for Photon Manipulation in Living Lighting Devices.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Transfer learning with pre-trained language models for protein expression level prediction inSynthetic and systems biotechnology · 2026Article
- Review
- Low inducer concentrations at 10 °C promotes soluble recombinant expression of Aedes aegypti mosquito midgut proteases in E. coli.Microbial cell factories · 2026Article
- Modulating 6 S RNA improves recombinant protein yield in Escherichia coli at lower temperatures.World journal of microbiology & biotechnology · 2026Article
- Multienzyme Platform for the Synthesis of UDP Sugars and Human Milk Oligosaccharides.Chembiochem : a European journal of chemical biology · 2026Article
- Effective degradation of aflatoxin BWorld journal of microbiology & biotechnology · 2026Article
- Plant-derived vaccines for veterinary disease management in ruminants and swine.Biotechnology letters · 2026Review
- Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization.Molecular biotechnology · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026Review
- Precision hydrolysis: tailored yeast processing enzymes for yeast-based products.Applied microbiology and biotechnology · 2026Review
- Expression of Recombinant Phytoplasma Proteins in E. coli.Methods in molecular biology (Clifton, N.J.) · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of recombinant proteins is one of the most significant achievements of biotechnology in the last century. These proteins are produced in the eukaryotic or prokaryotic heterologous hosts. By increasing the omics data especially related to different heterologous hosts as well as the presence of new amenable genetic engineering tools, we can artificially engineer heterologous hosts to produce recombinant proteins in sufficient quantities. Numerous recombinant proteins have been produced and applied in various industries, and the global recombinant proteins market size is expected to be cast to reach USD 2.4 billion by 2027. Therefore, identifying the weakness and strengths of heterologous hosts is critical to optimize the large-scale biosynthesis of recombinant proteins. E. coli is one of the popular hosts to produce recombinant proteins. Scientists reported some bottlenecks in this host, and due to the increasing demand for the production of recombinant proteins, there is an urgent need to improve this host. In this review, we first provide general information about the E. coli host and compare it with other hosts. In the next step, we describe the factors involved in the expression of the recombinant proteins in E. coli. Successful expression of recombinant proteins in E. coli requires a complete elucidation of these factors. Here, the characteristics of each factor will be fully described, and this information can help to improve the heterologous expression of recombinant proteins in E. coli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.